159P - Prognostic relevance of genetic variants involved in immune checkpoint in patients with colorectal cancer

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Colon Cancer
Cancer Immunology and Immunotherapy
Rectal Cancer
Translational Research
Presenter Jong Gwang Kim
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors J.G. Kim1, B.W. Kang2, Y.S. Chae2, S. Yoon1
  • 1Oncology/hematology, Kyungpook National University Medical Center, 702-210 - Daegu/KR
  • 2Hematology/oncology, Kyungpook National University Hospital, 700-721 - Daegu/KR

Abstract

Aim/Background

Genetic polymorphisms in genes involved in immune response have been known to affect in anti-tumor immune response. We systematically investigated the associations of 17 functional SNPs in a panel of 8 genes (CCL2, CCR2, NT5E, IDO1, CTLA4, LAG3, PDL1, and PDCD1) involved in immune response checkpoints with the survival outcome of Korean patients with colorectal cancers (CRC).

Methods

The genomic DNA from 668 patients with curatively resected CRC was analyzed by Sequenom MassARRAY, and tested the association with recurrence-free survival (RFS) and overall survival (OS).

Results

Among 17 SNPs, we found that the CCR2 rs4586 and PDCD1 rs10204525 influenced survival outcomes in patients with resectable CRC. The CCR2 rs4586 showed significant correlation with OS in recessive model in univariate as well as multivariate model. In addition, the PDCD1 rs10204525 also revealed significant association with RFS and OS in recessive model in univariate and maintained the significant impact in multivariate analysis.

Conclusions

In conclusion, the present results suggest that the genetic predisposition of the host might affect anti-tumor immune reaction in CRC. Furthermore, the results of this study may be help select a targets for novel drug development to promote immune response.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.